Posted inCardiology Clinical Updates
Sirolimus-Coated Balloon Angioplasty in Femoropopliteal Artery Disease Without Tissue Loss: Promising Secondary Outcomes from the SirPAD Trial
This secondary analysis of the SirPAD trial shows that sirolimus-coated balloon angioplasty significantly reduces 1-year target-lesion revascularization rates compared to uncoated balloons in femoropopliteal artery disease patients without tissue loss, suggesting a safer and more effective treatment option.